Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
A clinical-stage immunology company focused on infectious diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug combo aims to tackle stubborn hepatitis d
Disease control OngoingThis Phase 3 trial tests whether a combination of two drugs, tobevibart and elebsiran, can suppress hepatitis D virus in adults who are still infected despite taking bulevirtide. About 150 participants will receive the combo as injections. The main goal is to see if the virus bec…
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo aims to tame rare liver virus
Disease control OngoingThis phase 2 trial tests two experimental drugs, Elebsiran and Tobevibart, in 95 adults with chronic hepatitis D, a serious liver infection. Participants receive the drugs as injections along with a standard oral antiviral. The goal is to see if the combination can lower virus le…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug duo aims to control hard-to-treat hepatitis delta
Disease control OngoingThis phase 3 study tests whether a combination of two drugs, tobevibart and elebsiran, can control chronic hepatitis delta better than waiting for treatment. About 124 adults with the infection will receive either the combo therapy or delayed treatment. The goal is to see if the …
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug duo takes on rare liver virus in head-to-head trial
Disease control OngoingThis study tests whether a combination of two experimental drugs (Tobevibart and Elebsiran) works better than the current treatment Bulevirtide for people with chronic hepatitis D, a serious liver infection. About 100 adults with stable liver disease will receive either the combo…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC